Treatment of severe Raynaud's syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy.
OBJECTIVE
To determine the effect of re-injection of small samples of autologous blood, pretreated with heat, ozone and ultraviolet light (H-O-U therapy) in patients with severe Raynaud's syndrome.


METHODS
Open trial in 4 patients.


METHODS
Temperature/humidity controlled vascular laboratory.


METHODS
Severe Raynaud's syndrome of more than 5 years duration and defined as more than 5 attacks daily or 10 attacks in one week, at least half of which were painful and lasting for more than 30 minutes. Three patients were refractory to infusions of Iloprost.


METHODS
Patients were treated daily or on alternate days for a two to three weeks period by re-injection of citrated autologous blood pre-treated with heat, ozone and ultraviolet light (H-O-U therapy).


METHODS
Clinical observations; mean equilibrated hand temperature (infrared thermography); distributive and microcirculatory blood-flow (venous occlusion strain-gauge plethysmography, infrared photoplethysmography, laser Doppler flowmetry) iontophoresis of acetylcholine and sodium nitroprusside; estimations: serum levels of 6-keto-PGF1alpha and serum levels of anti-hsp65 antibody.


RESULTS
Reduction or abolition of Raynaud's attacks for at least three months after treatment. Mean equilibrated hand temperature increased but did not normalise. Blood flow parameters improved but did not reach statistical significance. Iontophoresis of acetylcholine showed an increase in laser Doppler flowmetry which was statistically significant. Serum levels of 6-keto-PGF1alpha, fell significantly in three patients. Serum levels of anti-hsp65 antibody fell in the one patient which was followed sequentially.


CONCLUSIONS
H-O-U therapy may prove useful in patients with severe Raynaud's syndrome.
Cooke
E D
ED
Clinical Microvascular Unit, St. Bartholomew's Hospital, London, UK.
Pockley
A G
AG
Tucker
A T
AT
Kirby
J D
JD
Bolton
A E
AE
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001426:Bacterial Proteins; D001769:Blood / Q000187:drug effects* / Q000528:radiation effects*; D001783:Blood Flow Velocity; D001804:Blood Transfusion, Autologous / Q000379:methods*; D018834:Chaperonin 60; D018833:Chaperonins / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006358:Hot Temperature / Q000627:therapeutic use*; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008875:Middle Aged; D010126:Ozone / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D013577:Syndrome; D014466:Ultraviolet Rays
D001426:Bacterial Proteins; D018834:Chaperonin 60; C074119:heat-shock protein 65, Mycobacterium; D015121:6-Ketoprostaglandin F1 alpha; D010126:Ozone; D018833:Chaperonins